Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) saw its shares make a solid gain to close out the year after the U.S. Food and Drug Administration (FDA) accepted for review the firm’s New Drug Application (NDA) for Azedra.
Azedra works to treat patients with malignant, recurrent or unresectable pheochromocytoma and paraganglioma, which are rare neuroendocrine tumors.
Previously, the FDA granted Progenics’ request for Priority Review and has set an action date of April 30, 2018 under the Prescription Drug User Fee Act (PDUFA).
The NDA is supported by data from a pivotal Phase 2b open-label, multi-center trial that was conducted under a Special Protocol Assessment (SPA) with the FDA. The trial met the primary endpoint evaluating the proportion of pheochromocytoma and paraganglioma patients who achieved a 50% or greater reduction of all antihypertensive medication for at least six months.
It also demonstrated favorable results from a key secondary endpoint evaluating the proportion of patients with overall tumor response as measured by response evaluation criteria in solid tumors. Azedra also was shown to be safe and generally well tolerated.
Mark Baker, CEO of Progenics, commented:
With no FDA-approved therapies for these rare tumors, AZEDRA has the potential to address the high unmet need of patients with malignant pheochromocytoma and paraganglioma. We are pleased that the FDA has accepted our NDA with Priority Review, and look forward to working with the Agency during the review process. At the same time, we will continue to lay the groundwork for our commercial plan and prepare to launch quickly following a potential approval.
Shares of Progenics were last seen up over 15% at $6.76, with a consensus analyst price target of $13.75 and a 52-week range of $4.60 to $11.72.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
